PT  - JOURNAL ARTICLE
AU  - Skei, Nina Vibeche
AU  - Lund Nilsen, Tom Ivar
AU  - Knoop, Siri Tandberg
AU  - Prescott, Hallie C.
AU  - Lydersen, Stian
AU  - Mohus, Randi Marie
AU  - Brkic, Alen
AU  - Liyanarachi, Kristin Vardheim
AU  - Solligård, Erik
AU  - Damås, Jan Kristian
AU  - Gustad, Lise Tuset
TI  - Long-term temporal trends in incidence rate and case fatality of sepsis and COVID-19-related sepsis: nationwide registry study
AID  - 10.1101/2022.11.18.22282501
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.18.22282501
4099  - http://medrxiv.org/content/early/2022/11/18/2022.11.18.22282501.short
4100  - http://medrxiv.org/content/early/2022/11/18/2022.11.18.22282501.full
AB  - Importance Sepsis is one of the leading causes of morbidity and mortality. The majority of sepsis cases is attributed to bacterial infections, but virus infections can also induce sepsis. Conflicting results in incidence rates and case fatality trends of sepsis is reported, and how the COVID-19 pandemic influenced these trends are unknown.Objective To estimate temporal trends in incidence rate and case fatality during a 14-year period from 2008 through 2021, and to assess possible shifts in these trends during the COVID-19 pandemic.Design A nationwide longitudinal registry study using ICD-10 discharge codes to identify sepsis.Setting All Norwegian hospitals from 2008 through 2021.Participants All sepsis cases included 317.705 patients and of these, 222.832 had a first sepsis episode.Main outcomes and measures Annual age-standardized incidence rates with 95% confidence intervals (CI). Poisson regression was used to estimate changes in incidence rates across time, and logistic regression was used to estimate odds ratios for in-hospital death.Results Among 12.619.803 adult hospitalizations, 317.705 (2.5%) patients met the sepsis criteria and 222.832 (70.0%) had a first sepsis episode. In the period 2009-2019, the annual incidence rate for a first sepsis episode was stable (incidence rate ratio per year, 0.999; 95% CI, 0.994-1.004), whereas for all sepsis the incidence rate increased by 15.5% during the period (annual incidence rate ratio, 1.013; 95% CI 1.007-1.019). During the COVID-19 pandemic, the incidence rate ratio for a first sepsis was 0.877 (95% CI, 0.829-0.927) in 2020 and 0.929 (95% CI, 0.870-0.992) in 2021, and for all sepsis it was 0.870 (95% CI, 0.810-0.935) in 2020 and 0.908 (95% CI, 0.840-0.980) in 2021, compared to the previous 11-year period. In-hospital deaths declined in the period 2009-2019 (odds ratio per year, 0.954 [95% CI,0.950-0.958]), whereas deaths increased during the COVID-19 pandemic in 2020 (odds ratios, 1.061 [95% CI 1.001-1.124] and in 2021 odds ratio (1.164 [95% CI, 1.098-1.233]).Conclusion and relevance We found a stable incidence rate of a first sepsis episode during the years 2009-2019. However, the increasing burden of all sepsis admissions indicates that sepsis awareness with updated guidelines and education must continue.Question Has there been a change in incidence rate and case fatality of sepsis over the past decade, and how did the COVID-19 pandemic influence sepsis incidence rates and in-hospital mortality?Findings In this nationwide longitudinal registry study the incidence rate of all sepsis episodes increased and the incidence rate of a first sepsis episode was stable during the period 2009-2019, whereas in 2020 and 2021, the incidence rate of a first and all sepsis episodes was lower than in the preceding 11-year period. Case fatality risk declined from 2009 to 2019, but increased somewhat in 2020 and 2021, when 9.7% of first sepsis cases were identified as COVID-19 related sepsis.Meaning Despite a stable incidence rate of first-time sepsis admissions over time, the burden of sepsis is rising due to an increased rate of patients admitted multiple times with sepsis. The COVID-19 pandemic have had an impact on sepsis incidence rate and hospital mortality and needs further evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Regional Committee for Medical and Health Research Ethics (REK) in Eastern Norway (2019/42772) and the Data Access Committee in Nord-Trondelag Hospital Trust (2021/184) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors